Early CA2 Tau Inclusions Do Not Distinguish an Age-Related Tauopathy from Early Alzheimer's Disease.

APOE Alzheimer’s disease Ammon’s horn CA2 PART hypothesis entorhinal cortex neurofibrillary tangles pretangles tau seeding tractus perforans

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
18 Sep 2024
Historique:
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 20 9 2024
Statut: aheadofprint

Résumé

Neuropathologic studies of brains from autopsy series show tau inclusions (pretangles, neuropils threads, neurofibrillary tangles) are detectable more than a decade before amyloid-β (Aβ) deposition in Alzheimer's disease (AD) and develop in a characteristic manner that forms the basis for AD staging. An alternative position views pathological tau without Aβ deposition as a 'primary age-related tauopathy' (PART) rather than prodromal AD. Recently, an early focus of tau inclusions in the Ammon's horn second sector (CA2) with relative sparing of CA1 that occurs before tau inclusions develop in the entorhinal cortex (EC) was proposed as an additional feature of PART. To test the 'definite PART' hypothesis. We used AT8-immunohistochemistry in 100μm sections to examine the EC, transentorhinal cortex (TRE), and Ammon's horn in 325 brains with tau inclusions lacking Aβ deposits (average age at death 66.7 years for females, 66.4 years for males). 100% of cases displayed tau inclusions in the TRE. In 89% of cases, the CA1 tau rating was greater than or equal to that in CA2. In 25%, CA2 was devoid of tau inclusions. Only 4% displayed a higher tau score in CA2 than in the TRE, EC, and CA1. The perforant path also displayed early tau changes. APOE genotyping was available for 199/325 individuals. Of these, 44% had an ɛ4 allele that placed them at greater risk for developing later NFT stages and, therefore, clinical AD. Our new findings call into question the PART hypothesis and are consistent with the idea that our cases represent prodromal AD.

Sections du résumé

Background UNASSIGNED
Neuropathologic studies of brains from autopsy series show tau inclusions (pretangles, neuropils threads, neurofibrillary tangles) are detectable more than a decade before amyloid-β (Aβ) deposition in Alzheimer's disease (AD) and develop in a characteristic manner that forms the basis for AD staging. An alternative position views pathological tau without Aβ deposition as a 'primary age-related tauopathy' (PART) rather than prodromal AD. Recently, an early focus of tau inclusions in the Ammon's horn second sector (CA2) with relative sparing of CA1 that occurs before tau inclusions develop in the entorhinal cortex (EC) was proposed as an additional feature of PART.
Objective UNASSIGNED
To test the 'definite PART' hypothesis.
Methods UNASSIGNED
We used AT8-immunohistochemistry in 100μm sections to examine the EC, transentorhinal cortex (TRE), and Ammon's horn in 325 brains with tau inclusions lacking Aβ deposits (average age at death 66.7 years for females, 66.4 years for males).
Results UNASSIGNED
100% of cases displayed tau inclusions in the TRE. In 89% of cases, the CA1 tau rating was greater than or equal to that in CA2. In 25%, CA2 was devoid of tau inclusions. Only 4% displayed a higher tau score in CA2 than in the TRE, EC, and CA1. The perforant path also displayed early tau changes. APOE genotyping was available for 199/325 individuals. Of these, 44% had an ɛ4 allele that placed them at greater risk for developing later NFT stages and, therefore, clinical AD.
Conclusions UNASSIGNED
Our new findings call into question the PART hypothesis and are consistent with the idea that our cases represent prodromal AD.

Identifiants

pubmed: 39302368
pii: JAD240483
doi: 10.3233/JAD-240483
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Kelly Del Tredici (K)

Clinical Neuroanatomy/Department of Neurology, Center for Biomedical Research, University of Ulm, Ulm, Germany.

Michael Schön (M)

Institute for Anatomy and Cell Biology, University of Ulm, Ulm, Germany.

Simone Feldengut (S)

Clinical Neuroanatomy/Department of Neurology, Center for Biomedical Research, University of Ulm, Ulm, Germany.

Estifanos Ghebremedhin (E)

Institute of Clinical Neuroanatomy, Goethe University Frankfurt, Frankfurt am Main, Germany.

Sarah K Kaufman (SK)

Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Diana Wiesner (D)

Department of Neurology, Ulm University, Ulm, Germany.
German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.

Francesco Roselli (F)

Department of Neurology, Ulm University, Ulm, Germany.
German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.

Benjamin Mayer (B)

Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.

Katrin Amunts (K)

Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany.
Cécile and Oskar Vogt Institute for Brain Research, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Heiko Braak (H)

Clinical Neuroanatomy/Department of Neurology, Center for Biomedical Research, University of Ulm, Ulm, Germany.

Classifications MeSH